EHElizabeth Hall-Lipsy

Elizabeth Hall-Lipsy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elizabeth Hall-Lipsy has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Educational and personal influences and barriers to practicing rural pharmacy

    by Heidi R. Olson, Alice N. Hemenway, Megan R. Undeberg, Elizabeth Hall-Lipsy, Allison E. Schriever, Kevin O. Rynn, Rachel Lane, Timothy P. Stratton

  • Open Access

    Building on the 2025 National Academies Pharmacy Workshop: pharmacy deserts in the United States

    by Lucas A Berenbrok, Delesha Carpenter, Teresa M Salgado, Marie Chisholm-Burns, Jenny S Guadamuz, Elizabeth Hall-Lipsy, Cherokee Layson-Wolf, Whitney D Maxwell, Heidi R Olson, Megan R Undeberg, et al.

    Areas with no access or limited access to community pharmacies are routinely referred to as “pharmacy deserts,” which are of growing concern in the United States. In addition to medication dispensing, community pharmacies offer a variety of healthcare services that keep populations and individuals healthy. Our objective is to present an overview of pharmacy deserts in the United States, discuss the impact of reduced pharmacy access for Americans, and propose solutions discussed at the 2025 Innovations in Pharmacy Training and Sustainable Practice to Advance Patient Care: A Workshop at the National Academies in Washington, D.C. Policy and legislation that ensure the financial sustainability of community pharmacies as staples of healthcare delivery in local neighborhoods should consider these multimodal solutions to ensure pharmacy access for all populations in the United States.

  • Open Access

    Features of Cancer mHealth Apps and Evidence for Patient Preferences: Scoping Literature Review

    by Shannon Vaffis, Soluna Whaley, David Rhys Axon, Elizabeth Hall-Lipsy, Ana Hincapie, Marion Slack, Terri Warholak

    Background: Cancer is increasingly being treated as a chronic disease rather than an acute one-time illness. Additionally, oral anticancer therapies, as opposed to intravenous chemotherapy, are now available for an increasing number of cancer indications. Mobile health (mHealth) apps for use on mobile devices (eg, smartphones or tablets) are designed to help patients with medication adherence, symptom tracking, and disease management. Several previous literature reviews have been conducted regarding mHealth apps for cancer. However, these studies did not address patient preferences for the features of cancer mHealth apps. Objective: The primary aim was to review the scientific literature that describes the features and functions of mHealth apps designed for cancer self-management. Methods: As the purpose of this review was to explore the depth and breadth of research on mHealth app features for cancer self-management, a scoping review methodology was adopted. Four databases were used for this review: PubMed/MEDLINE, Embase, CINAHL, and PsycINFO. Citation and reference searches were conducted for manuscripts meeting the inclusion criteria. A gray literature search was also conducted. Data extracted from manuscripts included author, title, publication date, study type, sampling type, cancer type, treatment, age of participants, features, availability (free or subscription), design input, and patient preferences. Finally, the features listed for each app were compared, highlighting similarities across platforms as well as features unique to each app. Results: After the removal of duplicates, 522 manuscripts remained for the title and abstract review, with 51 undergoing full-text review. A total of 7 manuscripts (referred to as studies hereafter) were included in the final scoping review. App features described in each study varied from 2 to 11, with a median of 4 features per app. The most reported feature was a symptom or side effect tracker, which was reported in 6 studies. Two apps specified the inclusion of patients and health care providers during the design, while 1 app noted that IT and communications experts provided design input. The utility of the apps for end users was measured in several ways, including acceptability (measuring the end users’ experience), usability (assessing the functionality and performance by observing real users completing tasks), or qualitative data (reports from end users collected from interviews or focus groups). Conclusions: This review explored the literature on cancer mHealth apps. Popular features within these mHealth apps include symptom trackers, cancer education, and medication trackers. However, these apps and features are often developed with little input from patients. Additionally, there is little information regarding patient preferences for the features of existing apps. While the number of cancer-related apps available for download continues to increase, further exploration of patient preferences for app features could result in apps that better meet patient disease self-management needs.


  • Open Access

    Features of Cancer mHealth Apps and Evidence for Patient Preferences: Scoping Literature Review (Preprint)

    by Shannon Vaffis, Soluna Whaley, David Rhys Axon, Elizabeth Hall-Lipsy, Ana Hincapie, Marion Slack, Terri Warholak

    BACKGROUND Cancer is increasingly being treated as a chronic disease rather than an acute one-time illness. Additionally, oral anticancer therapies, as opposed to intravenous chemotherapy, are now available for an increasing number of cancer indications. Mobile health (mHealth) apps for use on mobile devices (eg, smartphones or tablets) are designed to help patients with medication adherence, symptom tracking, and disease management. Several previous literature reviews have been conducted regarding mHealth apps for cancer. However, these studies did not address patient preferences for the features of cancer mHealth apps. OBJECTIVE The primary aim was to review the scientific literature that describes the features and functions of mHealth apps designed for cancer self-management. METHODS As the purpose of this review was to explore the depth and breadth of research on mHealth app features for cancer self-management, a scoping review methodology was adopted. Four databases were used for this review: PubMed/MEDLINE, Embase, CINAHL, and PsycINFO. Citation and reference searches were conducted for manuscripts meeting the inclusion criteria. A gray literature search was also conducted. Data extracted from manuscripts included author, title, publication date, study type, sampling type, cancer type, treatment, age of participants, features, availability (free or subscription), design input, and patient preferences. Finally, the features listed for each app were compared, highlighting similarities across platforms as well as features unique to each app. RESULTS After the removal of duplicates, 522 manuscripts remained for the title and abstract review, with 51 undergoing full-text review. A total of 7 manuscripts (referred to as studies hereafter) were included in the final scoping review. App features described in each study varied from 2 to 11, with a median of 4 features per app. The most reported feature was a symptom or side effect tracker, which was reported in 6 studies. Two apps specified the inclusion of patients and health care providers during the design, while 1 app noted that IT and communications experts provided design input. The utility of the apps for end users was measured in several ways, including acceptability (measuring the end users’ experience), usability (assessing the functionality and performance by observing real users completing tasks), or qualitative data (reports from end users collected from interviews or focus groups). CONCLUSIONS This review explored the literature on cancer mHealth apps. Popular features within these mHealth apps include symptom trackers, cancer education, and medication trackers. However, these apps and features are often developed with little input from patients. Additionally, there is little information regarding patient preferences for the features of existing apps. While the number of cancer-related apps available for download continues to increase, further exploration of patient preferences for app features could result in apps that better meet patient disease self-management needs.

  • Validation of a pre-/post-survey to measure change in student social justice attitudes and empathy

    by Shannon Vaffis, Elizabeth J. Anderson, Rebekah M. Fettkeather, Terri Warholak, Elizabeth Hall-Lipsy


  • Open Access

    Evaluation of an Academic-Community Partnership to Implement MTM Services in Rural Communities to Improve Pharmaceutical Care for Patients with Diabetes and/or Hypertension

    by Melissa Johnson, Rebecca Jastrzab, Jared Tate, Kate Johnson, Elizabeth Hall-Lipsy, Rose Martin, Ann M. Taylor, Terri Warholak

    BACKGROUND: Although the current methods of medication therapy management (MTM) delivery have demonstrably improved therapeutic, safety, economic, and humanistic health outcomes, patient- and prescriber-level barriers persist, limiting its reach and effectiveness. OBJECTIVE: To assess telephonic- and community-based clinical pharmacy services in improving health indicators for rural, underserved patients. METHODS: In 2014, an established MTM provider created a novel, collaborative pilot program with independent retail and community health center pharmacies to provide comprehensive, telephonic MTM services to rural Arizonans. This pilot program used a combined telephonic- and community-based pharmacist approach in the provision of MTM services for rural, underserved Arizona populations. Adults with diabetes mellitus and/or hypertension, seen by a prescriber or who filled prescriptions at a contracted, rural facility in 2014, were eligible to participate. Initial MTM telephonic consultations were conducted,...


  • Open Access

    Defamation lawsuits: academic sword or shield?

    by Elizabeth Hall‐Lipsy, Sarah Malanga

    Scientists and academics are used to defending their theories, methods, and results in the classroom, at conferences, and in peer‐reviewed publications. But Pieter Cohen, an assistant professor at Harvard Medical School, learned that he had to defend his research in a defamation suit while reading a supplement industry trade publication (Robins, 2017). Cohen is known as a “dogged detective” for scrutinizing dietary supplements and for advocating for their stricter oversight by the US Food and Drug Administration (FDA).